What’s holding up the Shire-Baxalta deal? One word: Taxes

Carly Helfand Shire and Baxalta both reportedly want to make a tie-up happen. So what's taking so long? According to the Financial Times, the potential deal now hinges ...

Wait for it–Shire could finally announce $32.5B Baxalta deal by Monday

Carly Helfand Could Shire's months-long pursuit of Baxalta finally be coming to a close? That's the word from Reuters, which says the Dublin drugmaker is preparing to announce ...

Merck buys out IOmet, adding new immuno-oncology tech

John Carroll Merck has snagged Edinburgh-based IOmet for an undisclosed sum, adding a preclinical pipeline of therapies that target the IDO/TDO pathways that may help spur an immune ...

Globalization: Another year closer to a worldwide network

John Carroll When AstraZeneca announced its move to create its third R&D hub in China, the pharma giant was following in the paths of some major rivals. It also represented another ...

Novartis backs $176M microbiome biotech fund

John Carroll Novartis has stepped in to back Paris-based Seventure Partners' biotech fund focused exclusively on the emerging field of the microbiome as well as nutrition, bringing ...

Sanofi gets first approval for long-anticipated vaccine against dengue fever

Eric Palmer After two decades and $ 1.65 billion in research, French drugmaker Sanofi has gotten an approval for the world's first vaccine against the sometimes deadly dengue fever, ...

UPDATED: Alexion grabs an FDA OK–the 41st of ’15–for rare-disease drug Kanuma

John Carroll Seven months after Alexion bagged the rare-disease drug Kanuma in its $ 8.4 billion buyout of Synageva, the FDA has come through with a marketing approval. The agency ...

Daiichi Sankyo shuts down a German R&D shop

Damian Garde Daiichi Sankyo is closing up its German research outpost, shuttering the former U3 Pharma as it consolidates its global R&D presence. FierceBiotech News

Pfizer and Allergan wend toward a $150B merger, reports say

Tracy Staton Pfizer and Allergan are coming down to the wire on a merger that would be the biggest pharma deal ever. The all-stock transaction would be worth up to $ 150 billion, at ...

Isis and GlaxoSmithKline eye Phase III with a rare disease drug

Damian Garde GlaxoSmithKline and partner Isis Pharmaceuticals are plotting a pivotal trial in the rare TTR amyloid cardiomyopathy, an inherited disease that impairs the heart muscle. FierceBiotech ...

Grifols bags €100M for Alzheimer’s R&D; Ipsen inks $137M cancer deal; Oryzon raises €17M

Nick Paul Taylor In this week's EuroBiotech Report, Catalan biotech Grifols secured a €100 million ($ 110 million) loan from the European Investment Bank's €315 billion ...

UPDATED: Novartis falls short in controversial IPR process as board nixes Gilenya patent

Tracy Staton The U.S. Patent and Trademark Office's review board has dealt its first blow to Big Pharma. The appeal panel nixed a patent on Novartis' multiple sclerosis blockbuster ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS